Tag - ʻImi ʻImi Hou
Ua ʻae ʻo FDA i ka hoʻāʻo ʻana i ka maʻi maʻi maʻi hanu ʻeha
ʻO ka Laʻau Noʻonoʻo Hou no nā maʻi Leukemia Myeloid Acute
ʻO ka hoʻāʻo ʻāina hou no ka Phase 3 Acute Respiratory Distress Syndrome
ʻO ka hoʻāʻo hoʻāʻo hou no ka maʻi maʻi maʻi Lymphoblastic i hoʻihoʻi hou ʻia
ʻO ka hoʻāʻo hoʻāʻo hou o ka hoʻololi ʻana i ke kelepona i ka maʻi o Parkinson
Noiʻi hou e pili ana i ka hoʻohana ʻana i nā Psychedelics e hakakā i ka maʻi noʻonoʻo
ʻImi hou no ka mālama ʻana i ka maʻi maʻi pancreatic
Nā lāʻau lapaʻau hou no nā maʻi ʻā
ʻO ka immunotherapy hou no ka mālama ʻana i ka allergy pīkī
Non-Cystic Fibrosis Bronchiectasis ʻO ka hoʻāʻo lāʻau lapaʻau hou
Hoʻopaʻa haʻawina hou i ke ʻano haʻahaʻa a i ke koʻikoʻi o ka osteoarthritis o ka kuli
Hoʻomohala hou no ka lapaʻau ʻana i nā maʻi maʻi ʻo Retinal Vascular
ʻO ka hoʻāʻo hoʻāʻo hou o ka lāʻau noiʻi hou no ka mālama ʻana i ka alopecia
ʻO ka noiʻi lāʻau lapaʻau hou no ka maʻi hepatitis B
Investigational New Drug Application Therapy Targeting Life-Threatening E. coli Infections
ʻO ka maʻi ʻai Binge: ʻAe ʻia ka holomua o ka hoʻāʻo ʻana e ka FDA
ʻO ka mālama ʻana i ka maʻi cardiovascular genetic e hele ana i kahi hoʻomohala hou
